An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...
NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...
Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.
Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...
A new study reveals that nerve cells receive periodic infusions of mitochondria from neighboring cells — and this may point ...
Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics announced that CEO Patrice Rioux will present ...
According to a recent AHA Scientific Statement, despite ongoing limitations, recent advances in genomic sequencing ...
Despite being renowned as the “powerhouse of the cell,” mitochondria can also be a source of heartache for those living with mitochondrial disease—especially when planning to have children. Because ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback